Epidemiology of basal cell carcinoma: scholarly review

British Journal of Dermatology

Volumn 177, Issue 2, 2017, Pages 359-372

  Verkouteren, J A C ^a   Ramdas, K H R ^a   Wakkee, M ^a   Nijsten, T ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ARSENIC; PHOTOSENSITIZING AGENT; IMMUNOSUPPRESSIVE AGENT;

BASAL CELL CARCINOMA; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER REGISTRY; CARCINOGENESIS; DIET; ENVIRONMENTAL FACTOR; GENETIC PREDISPOSITION; GERMLINE MUTATION; GERMLINE POLYMORPHISM; GLOBAL DISEASE BURDEN; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IONIZING RADIATION; META ANALYSIS (TOPIC); PATIENT PREFERENCE; PHENOTYPE; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; RISK FACTOR; SECONDARY PREVENTION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SOMATIC MUTATION; SYSTEMATIC REVIEW (TOPIC); TERTIARY PREVENTION; TREATMENT OUTCOME; ULTRAVIOLET RADIATION; WART VIRUS; COST OF ILLNESS; DEMOGRAPHY; DRINKING BEHAVIOR; ECONOMICS; ENVIRONMENTAL EXPOSURE; GENETIC POLYMORPHISM; GENETICS; GLOBAL HEALTH; HEALTH CARE PLANNING; INCIDENCE; MUTATION; PAPILLOMAVIRUS INFECTION; PROCEDURES; SKIN TUMOR;

ALCOHOL DRINKING; CARCINOMA, BASAL CELL; COST OF ILLNESS; DIET; ENVIRONMENTAL EXPOSURE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; GLOBAL HEALTH; HEALTH CARE COSTS; HEALTH PRIORITIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MUTATION; PAPILLOMAVIRUS INFECTIONS; PHENOTYPE; PHOTOSENSITIZING AGENTS; POLYMORPHISM, GENETIC; PRIMARY PREVENTION; RADIATION, IONIZING; RESIDENCE CHARACTERISTICS; RISK FACTORS; SECONDARY PREVENTION; SKIN NEOPLASMS; SMOKING; ULTRAVIOLET RAYS;

EID: 85013472260     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.15321     Document Type: Review

References (222)

1. Peterson SC, Eberl M, Vagnozzi AN et al. Basal cell carcinoma preferentially arises from stem cells within hair follicle and mechanosensory niches. Cell Stem Cell 2015; 16:400–12.
2. Youssef KK, Van Keymeulen A, Lapouge G et al. Identification of the cell lineage at the origin of basal cell carcinoma. Nat Cell Biol 2010; 12:299–305.
3. Bastiaens MT, Hoefnagel JJ, Bruijn JA et al. Differences in age, site distribution, and sex between nodular and superficial basal cell carcinoma indicate different types of tumors. J Invest Dermatol 1998; 110:880–4.
4. Scrivener Y, Grosshans E, Cribier B. Variations of basal cell carcinomas according to gender, age, location and histopathological subtype. Br J Dermatol 2002; 147:41–7.
5. Betti R, Radaelli G, Crosti C et al. Margin involvement and clinical pattern of basal cell carcinoma with mixed histology. J Eur Acad Dermatol Venereol 2012; 26:483–7.
6. Arits AH, Schlangen MH, Nelemans PJ et al. Trends in the incidence of basal cell carcinoma by histopathological subtype. J Eur Acad Dermatol Venereol 2011; 25:565–9.
7. Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol 2012; 166:1069–80.
8. Rogers HW, Weinstock MA, Feldman SR et al. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S. population, 2012. JAMA Dermatol 2015; 151:1081–6.
9. American Cancer Society. Key statistics for basal and squamous cell skin cancers. Available at: http://www.cancer.org/cancer/skincancer-basalandsquamouscell/detailedguide/skin-cancer-basal-and-squamous-cell-key-statistics (last accessed 23 December 2016).
10. Staples MP, Elwood M, Burton RC et al. Non-melanoma skin cancer in Australia: the 2002 national survey and trends since 1985. Med J Aust 2006; 184:6–10.
11. Cancer Council Australia. Skin cancer. Available at: http://www.cancer.org.au/about-cancer/types-of-cancer/skin-cancer.html (last accessed 23 December 2016).
12. Rawashdeh MA, Matalka I. Basal cell carcinoma of the maxillofacial region: site distribution and incidence rates in Arab/Jordanians, 1991 to 2000. J Oral Maxillofac Surg 2004; 62:145–9.
13. Abarca JF, Casiccia CC. Skin cancer and ultraviolet-B radiation under the Antarctic ozone hole: southern Chile, 1987–2000. Photodermatol Photoimmunol Photomed 2002; 18:294–302.
14. Holterhues C, Vries E, Louwman MW et al. Incidence and trends of cutaneous malignancies in the Netherlands, 1989–2005. J Invest Dermatol 2010; 130:1807–12.
15. Christenson LJ, Borrowman TA, Vachon CM et al. Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA 2005; 294:681–90.
16. Birch-Johansen F, Jensen A, Mortensen L et al. Trends in the incidence of nonmelanoma skin cancer in Denmark 1978–2007: rapid incidence increase among young Danish women. Int J Cancer 2010; 127:2190–8.
17. Flohil SC, Seubring I, van Rossum MM et al. Trends in basal cell carcinoma incidence rates: a 37-year Dutch observational study. J Invest Dermatol 2013; 133:913–18.
18. Robinson JK, Rigel DS, Amonette RA. Trends in sun exposure knowledge, attitudes, and behaviors: 1986 to 1996. J Am Acad Dermatol 1997; 37:179–86.
19. Koster B, Thorgaard C, Clemmensen IH et al. Sunbed use in the Danish population in 2007: a cross-sectional study. Prev Med 2009; 48:288–90.
20. Swetter SM, Layton CJ, Johnson TM et al. Gender differences in melanoma awareness and detection practices between middle-aged and older men with melanoma and their female spouses. Arch Dermatol 2009; 145:488–90.
21. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953; 6:963–8.
22. Karagas MR, Stukel TA, Greenberg ER et al. Risk of subsequent basal cell carcinoma and squamous cell carcinoma of the skin among patients with prior skin cancer. Skin Cancer Prevention Study Group. JAMA 1992; 267:3305–10.
23. Flohil SC, van der Leest RJ, Arends LR et al. Risk of subsequent cutaneous malignancy in patients with prior keratinocyte carcinoma: a systematic review and meta-analysis. Eur J Cancer 2013; 49:2365–75.
24. Keim U, van der Pols JC, Williams GM et al. Exclusive development of a single type of keratinocyte skin cancer: evidence from an Australian population-based cohort study. J Invest Dermatol 2015; 135:728–33.
25. Weinstock MA, Lee KC, Chren MM et al. Quality of life in the actinic neoplasia syndrome: the VA Topical Tretinoin Chemoprevention (VATTC) trial. J Am Acad Dermatol 2009; 61:207–15.
26. Murray CJL, Lopez AD. The Global Burden of Disease: A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020, Vol. I. Cambridge, MA: The Harvard School of Public Health on behalf of the World Health Organization and the World Bank, 1996.
27. Lo JS, Snow SN, Reizner GT et al. Metastatic basal cell carcinoma: report of twelve cases with a review of the literature. J Am Acad Dermatol 1991; 24:715–19.
28. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 386:743–800.
29. Lucas RM, McMichael AJ, Armstrong BK et al. Estimating the global disease burden due to ultraviolet radiation exposure. Int J Epidemiol 2008; 37:654–67.
30. Hollestein LM, de Vries E, Aarts MJ et al. Burden of disease caused by keratinocyte cancer has increased in the Netherlands since 1989. J Am Acad Dermatol 2014; 71:896–903.
31. Gordon LG, Rowell D. Health system costs of skin cancer and cost-effectiveness of skin cancer prevention and screening: a systematic review. Eur J Cancer Prev 2015; 24:141–9.
32. Housman TS, Feldman SR, Williford PM et al. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol 2003; 48:425–9.
33. Guy GP, Ekwueme DU. Years of potential life lost and indirect costs of melanoma and non-melanoma skin cancer: a systematic review of the literature. Pharmacoeconomics 2011; 29:863–74.
34. Guy GP Jr, Machlin SR, Ekwueme DU et al. Prevalence and costs of skin cancer treatment in the U.S., 2002–2006 and 2007–2011. Am J Prev Med 2015; 48:183–7.
35. Stern RS. Cost effectiveness of Mohs micrographic surgery. J Invest Dermatol 2013; 133:1129–31.
36. Donaldson MR, Coldiron BM. Mohs micrographic surgery utilization in the Medicare population, 2009. Dermatol Surg 2012; 38:1427–34.
37. Mosterd K, Krekels GA, Nieman FH et al. Surgical excision versus Mohs’ micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years’ follow-up. Lancet Oncol 2008; 9:1149–56.
38. van Loo E, Mosterd K, Krekels GA et al. Surgical excision versus Mohs’ micrographic surgery for basal cell carcinoma of the face: a randomised clinical trial with 10 year follow-up. Eur J Cancer 2014; 50:3011–20.
39. Nijsten T. Commentary on ‘Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial’. Br J Dermatol 2015; 172:12.
40. Arits AH, Mosterd K, Essers BA et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol 2013; 14:647–54.
41. Arits AH, Spoorenberg E, Mosterd K et al. Cost-effectiveness of topical imiquimod and fluorouracil vs. photodynamic therapy for treatment of superficial basal-cell carcinoma. Br J Dermatol 2014; 171:1501–7.
42. Ioannidis JP. Why most published research findings are false. PLoS Med 2005; 2:e124.
43. Olsen CM, Wilson LF, Green AC et al. Cancers in Australia attributable to exposure to solar ultraviolet radiation and prevented by regular sunscreen use. Aust N Z J Public Health 2015; 39:471–6.
44. Gallagher RP, Hill GB, Bajdik CD et al. Sunlight exposure, pigmentary factors, and risk of nonmelanocytic skin cancer. I. Basal cell carcinoma. Arch Dermatol 1995; 131:157–63.
45. Kricker A, Armstrong BK, English DR et al. Does intermittent sun exposure cause basal cell carcinoma? A case–control study in Western Australia. Int J Cancer 1995; 60:489–94.
46. Kricker A, Armstrong BK, English DR et al. A dose–response curve for sun exposure and basal cell carcinoma. Int J Cancer 1995; 60:482–8.
47. Rosso S, Zanetti R, Martinez C et al. The multicentre south European study ‘Helios’. II: Different sun exposure patterns in the aetiology of basal cell and squamous cell carcinomas of the skin. Br J Cancer 1996; 73:1447–54.
48. van Dam RM, Huang Z, Rimm EB et al. Risk factors for basal cell carcinoma of the skin in men: results from the health professionals follow-up study. Am J Epidemiol 1999; 150:459–68.
49. Naldi L, DiLandro A, D'Avanzo B et al. Host-related and environmental risk factors for cutaneous basal cell carcinoma: evidence from an Italian case–control study. J Am Acad Dermatol 2000; 42:446–52.
50. Wehner MR, Shive ML, Chren MM et al. Indoor tanning and non-melanoma skin cancer: systematic review and meta-analysis. BMJ 2012; 345:e5909.
51. Stern RS; PUVA Follow-Up Study. The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study. J Am Acad Dermatol 2012; 66:553–62.
52. Bruynzeel I, Bergman W, Hartevelt HM et al. ‘High single-dose’ European PUVA regimen also causes an excess of non-melanoma skin cancer. Br J Dermatol 1991; 124:49–55.
53. Nijsten TE, Stern RS. The increased risk of skin cancer is persistent after discontinuation of psoralen+ultraviolet A: a cohort study. J Invest Dermatol 2003; 121:252–8.
54. Man I, Crombie IK, Dawe RS et al. The photocarcinogenic risk of narrowband UVB (TL-01) phototherapy: early follow-up data. Br J Dermatol 2005; 152:755–7.
55. Ruiter R, Visser LE, Eijgelsheim M et al. High-ceiling diuretics are associated with an increased risk of basal cell carcinoma in a population-based follow-up study. Eur J Cancer 2010; 46:2467–72.
56. Robinson SN, Zens MS, Perry AE et al. Photosensitizing agents and the risk of non-melanoma skin cancer: a population-based case–control study. J Invest Dermatol 2013; 133:1950–5.
57. McDonald E, Freedman DM, Alexander BH et al. Prescription diuretic use and risk of basal cell carcinoma in the nationwide U.S. radiologic technologists cohort. Cancer Epidemiol Biomarkers Prev 2014; 23:1539–45.
58. Ron E, Modan B, Preston D et al. Radiation-induced skin carcinomas of the head and neck. Radiat Res 1991; 125:318–25.
59. Karagas MR, McDonald JA, Greenberg ER et al. Risk of basal cell and squamous cell skin cancers after ionizing radiation therapy. For The Skin Cancer Prevention Study Group. J Natl Cancer Inst 1996; 88:1848–53.
60. Ronckers CM, Land CE, Hayes RB et al. Late health effects of childhood nasopharyngeal radium irradiation: nonmelanoma skin cancers, benign tumors, and hormonal disorders. Pediatr Res 2002; 52:850–8.
61. Shore RE, Moseson M, Xue X et al. Skin cancer after X-ray treatment for scalp ringworm. Radiat Res 2002; 157:410–18.
62. Watt TC, Inskip PD, Stratton K et al. Radiation-related risk of basal cell carcinoma: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2012; 104:1240–50.
63. Leisenring W, Friedman DL, Flowers ME et al. Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation. J Clin Oncol 2006; 24:1119–26.
64. Sugiyama H, Misumi M, Kishikawa M et al. Skin cancer incidence among atomic bomb survivors from 1958 to 1996. Radiat Res 2014; 181:531–9.
65. Yoshinaga S, Hauptmann M, Sigurdson AJ et al. Nonmelanoma skin cancer in relation to ionizing radiation exposure among U.S. radiologic technologists. Int J Cancer 2005; 115:828–34.
66. Lichter MD, Karagas MR, Mott LA et al. Therapeutic ionizing radiation and the incidence of basal cell carcinoma and squamous cell carcinoma. The New Hampshire Skin Cancer Study Group. Arch Dermatol 2000; 136:1007–11.
67. Maloney ME. Arsenic in dermatology. Dermatol Surg 1996; 22:301–4.
68. Guo HR, Yu HS, Hu H et al. Arsenic in drinking water and skin cancers: cell-type specificity (Taiwan, ROC). Cancer Causes Control 2001; 12:909–16.
69. Leonardi G, Vahter M, Clemens F et al. Inorganic arsenic and basal cell carcinoma in areas of Hungary, Romania, and Slovakia: a case–control study. Environ Health Perspect 2012; 120:721–6.
70. Leonardi-Bee J, Ellison T, Bath-Hextall F. Smoking and the risk of nonmelanoma skin cancer: systematic review and meta-analysis. Arch Dermatol 2012; 148:939–46.
71. Song F, Qureshi AA, Gao X et al. Smoking and risk of skin cancer: a prospective analysis and a meta-analysis. Int J Epidemiol 2012; 41:1694–705.
72. Iftner A, Klug SJ, Garbe C et al. The prevalence of human papillomavirus genotypes in nonmelanoma skin cancers of nonimmunosuppressed individuals identifies high-risk genital types as possible risk factors. Cancer Res 2003; 63:7515–19.
73. Feltkamp MC, Broer R, di Summa FM et al. Seroreactivity to epidermodysplasia verruciformis-related human papillomavirus types is associated with nonmelanoma skin cancer. Cancer Res 2003; 63:2695–700.
74. Iannacone MR, Gheit T, Waterboer T et al. Case–control study of cutaneous human papillomavirus infection in basal cell carcinoma of the skin. J Invest Dermatol 2013; 133:1512–20.
75. Wieland U, Ritzkowsky A, Stoltidis M et al. Communication: papillomavirus DNA in basal cell carcinomas of immunocompetent patients: an accidental association? J Invest Dermatol 2000; 115:124–8.
76. Karagas MR, Waterboer T, Li Z et al. Genus beta human papillomaviruses and incidence of basal cell and squamous cell carcinomas of skin: population based case–control study. BMJ 2010; 341:c2986.
77. Andersson K, Luostarinen T, Strand AS et al. Prospective study of genital human papillomaviruses and nonmelanoma skin cancer. Int J Cancer 2013; 133:1840–5.
78. Harwood CA, Proby CM. Human papillomaviruses and non-melanoma skin cancer. Curr Opin Infect Dis 2002; 15:101–14.
79. McNaughton SA, Marks GC, Green AC. Role of dietary factors in the development of basal cell cancer and squamous cell cancer of the skin. Cancer Epidemiol Biomarkers Prev 2005; 14:1596–607.
80. Knekt P, Aromaa A, Maatela J et al. Serum selenium and subsequent risk of cancer among Finnish men and women. J Natl Cancer Inst 1990; 82:864–8.
81. Wei Q, Matanoski GM, Farmer ER et al. Vitamin supplementation and reduced risk of basal cell carcinoma. J Clin Epidemiol 1994; 47:829–36.
82. van Dam RM, Huang Z, Giovannucci E et al. Diet and basal cell carcinoma of the skin in a prospective cohort of men. Am J Clin Nutr 2000; 71:135–41.
83. Davies TW, Treasure FP, Welch AA et al. Diet and basal cell skin cancer: results from the EPIC-Norfolk cohort. Br J Dermatol 2002; 146:1017–22.
84. Fung TT, Hunter DJ, Spiegelman D et al. Vitamins and carotenoids intake and the risk of basal cell carcinoma of the skin in women (United States). Cancer Causes Control 2002; 13:221–30.
85. Fung TT, Hunter DJ, Spiegelman D et al. Intake of alcohol and alcoholic beverages and the risk of basal cell carcinoma of the skin. Cancer Epidemiol Biomarkers Prev 2002; 11:1119–22.
86. Freedman DM, Sigurdson A, Doody MM et al. Risk of basal cell carcinoma in relation to alcohol intake and smoking. Cancer Epidemiol Biomarkers Prev 2003; 12:1540–3.
87. Ansems TM, van der Pols JC, Hughes MC et al. Alcohol intake and risk of skin cancer: a prospective study. Eur J Clin Nutr 2008; 62:162–70.
88. Jensen A, Birch-Johansen F, Olesen AB et al. Intake of alcohol may modify the risk for non-melanoma skin cancer: results of a large Danish prospective cohort study. J Invest Dermatol 2012; 132:2718–26.
89. Zhang Y, Ferrucci LM, Cartmel B et al. Alcohol intake and early-onset basal cell carcinoma in a case–control study. Br J Dermatol 2014; 171:1451–7.
90. Jacobsen BK, Bjelke E, Kvale G et al. Coffee drinking, mortality, and cancer incidence: results from a Norwegian prospective study. J Natl Cancer Inst 1986; 76:823–31.
91. Song F, Qureshi AA, Han J. Increased caffeine intake is associated with reduced risk of basal cell carcinoma of the skin. Cancer Res 2012; 72:3282–9.
92. Verkouteren JA, Smedinga H, Steyerberg EW et al. Predicting the risk of a second basal cell carcinoma. J Invest Dermatol 2015; 135:2649–56.
93. Mirza SS, Tiemeier H, de Bruijn RF et al. Coffee consumption and incident dementia. Eur J Epidemiol 2014; 29:735–41.
94. Hartevelt MM, Bavinck JN, Kootte AM et al. Incidence of skin cancer after renal transplantation in the Netherlands. Transplantation 1990; 49:506–9.
95. Singh H, Nugent Z, Demers AA et al. Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology 2011; 141:1612–20.
96. Jensen AO, Thomsen HF, Engebjerg MC et al. Use of oral glucocorticoids and risk of skin cancer and non-Hodgkin's lymphoma: a population-based case–control study. Br J Cancer 2009; 100:200–5.
97. Jemec GB, Holm EA. Nonmelanoma skin cancer in organ transplant patients. Transplantation 2003; 75:253–7.
98. Moloney FJ, Comber H, O'Lorcain P et al. A population-based study of skin cancer incidence and prevalence in renal transplant recipients. Br J Dermatol 2006; 154:498–504.
99. Wisgerhof HC, Edelbroek JR, de Fijter JW et al. Subsequent squamous- and basal-cell carcinomas in kidney-transplant recipients after the first skin cancer: cumulative incidence and risk factors. Transplantation 2010; 89:1231–8.
100. Asgari MM, Moffet HH, Ray GT et al. Trends in basal cell carcinoma incidence and identification of high-risk subgroups, 1998–2012. JAMA Dermatol 2015; 151:976–81.
101. Wei Q, Matanoski GM, Farmer ER et al. DNA repair and aging in basal cell carcinoma: a molecular epidemiology study. Proc Natl Acad Sci U S A 1993; 90:1614–18.
102. Moriwaki S, Ray S, Tarone RE et al. The effect of donor age on the processing of UV-damaged DNA by cultured human cells: reduced DNA repair capacity and increased DNA mutability. Mutat Res 1996; 364:117–23.
103. Zanetti R, Rosso S, Martinez C et al. The multicentre south European study ‘Helios’. I: Skin characteristics and sunburns in basal cell and squamous cell carcinomas of the skin. Br J Cancer 1996; 73:1440–6.
104. Dwyer T, Blizzard L, Ashbolt R et al. Cutaneous melanin density of Caucasians measured by spectrophotometry and risk of malignant melanoma, basal cell carcinoma, and squamous cell carcinoma of the skin. Am J Epidemiol 2002; 155:614–21.
105. Zanetti R, Rosso S, Martinez C et al. Comparison of risk patterns in carcinoma and melanoma of the skin in men: a multi-centre case–case–control study. Br J Cancer 2006; 94:743–51.
106. Dessinioti C, Tzannis K, Sypsa V et al. Epidemiologic risk factors of basal cell carcinoma development and age at onset in a Southern European population from Greece. Exp Dermatol 2011; 20:622–6.
107. Qureshi AA, Zhang M, Han J. Heterogeneity in host risk factors for incident melanoma and non-melanoma skin cancer in a cohort of US women. J Epidemiol 2011; 21:197–203.
108. Walther U, Kron M, Sander S et al. Risk and protective factors for sporadic basal cell carcinoma: results of a two-centre case–control study in southern Germany. Clinical actinic elastosis may be a protective factor. Br J Dermatol 2004; 151:170–8.
109. Green A, Battistutta D, Hart V et al. Skin cancer in a subtropical Australian population: incidence and lack of association with occupation. The Nambour Study Group. Am J Epidemiol 1996; 144:1034–40.
110. de Vries E, Trakatelli M, Kalabalikis D et al. Known and potential new risk factors for skin cancer in European populations: a multicentre case–control study. Br J Dermatol 2012; 167 (Suppl. 2):1–13.
111. Khalesi M, Whiteman DC, Tran B et al. A meta-analysis of pigmentary characteristics, sun sensitivity, freckling and melanocytic nevi and risk of basal cell carcinoma of the skin. Cancer Epidemiol 2013; 37:534–43.
112. Lovatt TJ, Lear JT, Bastrilles J et al. Associations between UVR exposure and basal cell carcinoma site and histology. Cancer Lett 2004; 216:191–7.
113. Neale RE, Davis M, Pandeya N et al. Basal cell carcinoma on the trunk is associated with excessive sun exposure. J Am Acad Dermatol 2007; 56:380–6.
114. Richmond-Sinclair NM, Pandeya N, Williams GM et al. Clinical signs of photodamage are associated with basal cell carcinoma multiplicity and site: a 16-year longitudinal study. Int J Cancer 2010; 127:2622–9.
115. Flohil SC, Koljenovic S, de Haas ER et al. Cumulative risks and rates of subsequent basal cell carcinomas in the Netherlands. Br J Dermatol 2011; 165:874–81.
116. Robinson JK. Risk of developing another basal cell carcinoma. A 5-year prospective study. Cancer 1987; 60:118–20.
117. Lovatt TJ, Lear JT, Bastrilles J et al. Associations between ultraviolet radiation, basal cell carcinoma site and histology, host characteristics, and rate of development of further tumors. J Am Acad Dermatol 2005; 52:468–73.
118. Dahabreh IJ, Kent DM. Index event bias as an explanation for the paradoxes of recurrence risk research. JAMA 2011; 305:822–3.
119. Jayaraman SS, Rayhan DJ, Hazany S et al. Mutational landscape of basal cell carcinomas by whole-exome sequencing. J Invest Dermatol 2014; 134:213–20.
120. Alexandrov LB, Nik-Zainal S, Wedge DC et al. Signatures of mutational processes in human cancer. Nature 2013; 500:415–21.
121. van der Schroeff JG, Evers LM, Boot AJ et al. Ras oncogene mutations in basal cell carcinomas and squamous cell carcinomas of human skin. J Invest Dermatol 1990; 94:423–5.
122. Pierceall WE, Goldberg LH, Tainsky MA et al. Ras gene mutation and amplification in human nonmelanoma skin cancers. Mol Carcinog 1991; 4:196–202.
123. Campbell C, Quinn AG, Rees JL. Codon 12 Harvey-ras mutations are rare events in non-melanoma human skin cancer. Br J Dermatol 1993; 128:111–14.
124. Hahn H, Wicking C, Zaphiropoulous PG et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996; 85:841–51.
125. Johnson RL, Rothman AL, Xie J et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 1996; 272:1668–71.
126. Gailani MR, Bale SJ, Leffell DJ et al. Developmental defects in Gorlin syndrome related to a putative tumor suppressor gene on chromosome 9. Cell 1992; 69:111–17.
127. van der Riet P, Karp D, Farmer E et al. Progression of basal cell carcinoma through loss of chromosome 9q and inactivation of a single p53 allele. Cancer Res 1994; 54:25–7.
128. Quinn AG, Campbell C, Healy E et al. Chromosome 9 allele loss occurs in both basal and squamous cell carcinomas of the skin. J Invest Dermatol 1994; 102:300–3.
129. Gailani MR, Bale AE. Developmental genes and cancer: role of patched in basal cell carcinoma of the skin. J Natl Cancer Inst 1997; 89:1103–9.
130. Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer 2008; 8:743–54.
131. Bieging KT, Mello SS, Attardi LD. Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer 2014; 14:359–70.
132. Vogelstein B. Cancer. A deadly inheritance. Nature 1990; 348:681–2.
133. Rady P, Scinicariello F, Wagner RF Jr et al. p53 mutations in basal cell carcinomas. Cancer Res 1992; 52:3804–6.
134. Ziegler A, Leffell DJ, Kunala S et al. Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. Proc Natl Acad Sci U S A 1993; 90:4216–20.
135. Bastiaens MT, ter Huurne JA, Kielich C et al. Melanocortin-1 receptor gene variants determine the risk of nonmelanoma skin cancer independently of fair skin and red hair. Am J Hum Genet 2001; 68:884–94.
136. Box NF, Duffy DL, Irving RE et al. Melanocortin-1 receptor genotype is a risk factor for basal and squamous cell carcinoma. J Invest Dermatol 2001; 116:224–9.
137. Han J, Kraft P, Colditz GA et al. Melanocortin 1 receptor variants and skin cancer risk. Int J Cancer 2006; 119:1976–84.
138. Gudbjartsson DF, Sulem P, Stacey SN et al. ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma. Nat Genet 2008; 40:886–91.
139. Stacey SN, Gudbjartsson DF, Sulem P et al. Common variants on 1p36 and 1q42 are associated with cutaneous basal cell carcinoma but not with melanoma or pigmentation traits. Nat Genet 2008; 40:1313–18.
140. Rafnar T, Sulem P, Stacey SN et al. Sequence variants at the TERT–CLPTM1L locus associate with many cancer types. Nat Genet 2009; 41:221–7.
141. Nan H, Xu M, Kraft P et al. Genome-wide association study identifies novel alleles associated with risk of cutaneous basal cell carcinoma and squamous cell carcinoma. Hum Mol Genet 2011; 20:3718–24.
142. Stacey SN, Sulem P, Jonasdottir A et al. A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nat Genet 2011; 43:1098–103.
143. Stacey SN, Sulem P, Gudbjartsson DF et al. Germline sequence variants in TGM3 and RGS22 confer risk of basal cell carcinoma. Hum Mol Genet 2014; 23:3045–53.
144. Stacey SN, Helgason H, Gudjonsson SA et al. New basal cell carcinoma susceptibility loci. Nat Commun 2015; 6:6825.
145. Verkouteren JA, Pardo LM, Uitterlinden AG et al. Common variants affecting susceptibility to develop multiple basal cell carcinomas. J Invest Dermatol 2015; 135:2135–8.
146. Madan V, Hoban P, Strange RC et al. Genetics and risk factors for basal cell carcinoma. Br J Dermatol 2006; 154 (Suppl. 1):5–7.
147. Heagerty AH, Fitzgerald D, Smith A et al. Glutathione S-transferase GSTM1 phenotypes and protection against cutaneous tumours. Lancet 1994; 343:266–8.
148. Lear JT, Heagerty AH, Smith A et al. Multiple cutaneous basal cell carcinomas: glutathione S-transferase (GSTM1, GSTT1) and cytochrome P450 (CYP2D6, CYP1A1) polymorphisms influence tumour numbers and accrual. Carcinogenesis 1996; 17:1891–6.
149. Ramachandran S, Lear JT, Ramsay H et al. Presentation with multiple cutaneous basal cell carcinomas: association of glutathione S-transferase and cytochrome P450 genotypes with clinical phenotype. Cancer Epidemiol Biomarkers Prev 1999; 8:61–7.
150. Gorlin RJ. Nevoid basal-cell carcinoma syndrome. Medicine (Baltimore) 1987; 66:98–113.
151. Kimonis VE, Goldstein AM, Pastakia B et al. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet 1997; 69:299–308.
152. Gorlin RJ, Goltz RW. Multiple nevoid basal-cell epithelioma, jaw cysts and bifid rib. A syndrome. N Engl J Med 1960; 262:908–12.
153. Epstein JH, Fukuyama K, Reed WB et al. Defect in DNA synthesis in skin of patients with xeroderma pigmentosum demonstrated in vivo. Science 1970; 168:1477–8.
154. Kraemer KH, Lee MM, Scotto J. Xeroderma pigmentosum. Cutaneous, ocular, and neurologic abnormalities in 830 published cases. Arch Dermatol 1987; 123:241–50.
155. Bazex A, Dupré A, Christol B. Génodermatose complexe de type indétermine associant une hypotrichose, un état atrophodermique géneralisé et des dégénérescence cutanées multiples (épithéliomas basocellulaires). Bull Soc Fr Dermatol Syphiligr 1964; 71:206.
156. Gould DJ, Barker DJ. Follicular atrophoderma with multiple basal cell carcinomas (Bazex). Br J Dermatol 1978; 99:431–5.
157. Michaelsson G, Olsson E, Westermark P. The Rombo syndrome: a familial disorder with vermiculate atrophoderma, milia, hypotrichosis, trichoepitheliomas, basal cell carcinomas and peripheral vasodilation with cyanosis. Acta Derm Venereol 1981; 61:497–503.
158. van Steensel MA, Jaspers NG, Steijlen PM. A case of Rombo syndrome. Br J Dermatol 2001; 144:1215–18.
159. Stern RS, Weinstein MC, Baker SG. Risk reduction for nonmelanoma skin cancer with childhood sunscreen use. Arch Dermatol 1986; 122:537–45.
160. Green A, Williams G, Neale R et al. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet 1999; 354:723–9.
161. Marks R. Two decades of the public health approach to skin cancer control in Australia: why, how and where are we now? Australas J Dermatol 1999; 40:1–5.
162. Montague M, Borland R, Sinclair C. Slip! Slop! Slap! and SunSmart, 1980–2000: skin cancer control and 20 years of population-based campaigning. Health Educ Behav 2001; 28:290–305.
163. Marks R. Skin cancer control in the 1990's, from Slip! Slop! Slap! To sun smart. Australas J Dermatol 1990; 31:1–4.
164. Centers for Disease Control and Prevention. Indoor Tanning Is Not Safe. Available at: https://www.cdc.gov/cancer/skin/basic_info/indoor_tanning.htm (last accessed 23 December 2016).
165. Olsen CM, Williams PF, Whiteman DC. Turning the tide? Changes in treatment rates for keratinocyte cancers in Australia 2000 through 2011. J Am Acad Dermatol 2014; 71:21–6 e1.
166. Tsao AS, Kim ES, Hong WK. Chemoprevention of cancer. CA Cancer J Clin 2004; 54:150–80.
167. Greenberg ER, Baron JA, Stukel TA et al. A clinical trial of beta carotene to prevent basal-cell and squamous-cell cancers of the skin. The Skin Cancer Prevention Study Group. N Engl J Med 1990; 323:789–95.
168. Frieling UM, Schaumberg DA, Kupper TS et al. A randomized, 12-year primary-prevention trial of beta carotene supplementation for nonmelanoma skin cancer in the physician's health study. Arch Dermatol 2000; 136:179–84.
169. Duffield-Lillico AJ, Slate EH, Reid ME et al. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. J Natl Cancer Inst 2003; 95:1477–81.
170. Tangrea JA, Edwards BK, Taylor PR et al. Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: a multicenter clinical trial. Isotretinoin-Basal Cell Carcinoma Study Group. J Natl Cancer Inst 1992; 84:328–32.
171. Levine N, Moon TE, Cartmel B et al. Trial of retinol and isotretinoin in skin cancer prevention: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol Biomarkers Prev 1997; 6:957–61.
172. Zhang B, Liang X, Ye L et al. No chemopreventive effect of nonsteroidal anti-inflammatory drugs on nonmelanoma skin cancer: evidence from meta-analysis. PLoS One 2014; 9:e96887.
173. Hodak E, Ginzburg A, David M et al. Etretinate treatment of the nevoid basal cell carcinoma syndrome. Therapeutic and chemopreventive effect. Int J Dermatol 1987; 26:606–9.
174. Peck GL, DiGiovanna JJ, Sarnoff DS et al. Treatment and prevention of basal cell carcinoma with oral isotretinoin. J Am Acad Dermatol 1988; 19:176–85.
175. Kraemer KH, DiGiovanna JJ, Moshell AN et al. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 1988; 318:1633–7.
176. Tang JY, Mackay-Wiggan JM, Aszterbaum M et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 2012; 366:2180–8.
177. Wilson JMG, Jungner G. Principles and Practice of Screening for Disease. Geneva: World Health Organization, 1968.
178. US Preventive Services Task Force; Bibbins-Domingo K, Grossman DC, Curry SJ et al. Screening for Skin Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2016; 316:429–35.
179. Eisemann N, Waldmann A, Geller AC et al. Non-melanoma skin cancer incidence and impact of skin cancer screening on incidence. J Invest Dermatol 2014; 134:43–50.
180. Rose G. Rose's Strategy of Preventive Medicine. New York: Oxford University Press, 2008.
181. Robinson JK, Altman JS, Rademaker AW. Socioeconomic status and attitudes of 51 patients with giant basal and squamous cell carcinoma and paired controls. Arch Dermatol 1995; 131:428–31.
182. Shingler SL, Garside J, Samanta K et al. Utilities for advanced basal cell carcinoma. J Med Econ 2013; 16:777–83.
183. Esserman LJ, Thompson IM, Reid B et al. Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol 2014; 15:e234–42.
184. Beck M. Rethink the word ‘Cancer,’ panel says. The Wall Street Journal, 2014.
185. Wenger NS. Skin cancer and shared decision making: comment on ‘treatment of nonfatal conditions at the end of life’. JAMA Intern Med 2013; 173:1012–13.
186. van Rijsingen MC, van Bon B, van der Wilt GJ et al. The current and future role of general practitioners in skin cancer care: an assessment of 268 general practitioners. Br J Dermatol 2014; 170:1366–8.
187. American Academy of Dermatology. Ten things physicians and patients should question. Choosing Wisely, 2013. Released 29 October 2013 (1–5) and 19 August 2015 (6–10); sources updated 20 September 2016. Available at: http://www.choosingwisely.org/societies/american-academy-of-dermatology/ (last accessed 20 December 2016).
188. Rosenthal E. Patients’ costs skyrocket; specialists’ incomes soar. The New York Times, 2014.
189. Linos E, Parvataneni R, Stuart SE et al. Treatment of nonfatal conditions at the end of life: nonmelanoma skin cancer. JAMA Intern Med 2013; 173:1006–12.
190. Rose PW, Watson E. What is the value of routine follow-up after diagnosis and treatment of cancer? Br J Gen Pract 2009; 59:482–3.
191. Rowe DE, Carroll RJ, Day CL Jr. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol 1989; 15:315–28.
192. Walker P, Hill D. Surgical treatment of basal cell carcinomas using standard postoperative histological assessment. Australas J Dermatol 2006; 47:1–12.
193. Helgeson VS, Snyder P, Seltman H. Psychological and physical adjustment to breast cancer over 4 years: identifying distinct trajectories of change. Health Psychol 2004; 23:3–15.
194. Stanton AL. Psychosocial concerns and interventions for cancer survivors. J Clin Oncol 2006; 24:5132–7.
195. Marghoob A, Kopf AW, Bart RS et al. Risk of another basal cell carcinoma developing after treatment of a basal cell carcinoma. J Am Acad Dermatol 1993; 28:22–8.
196. Wehner MR, Linos E, Parvataneni R et al. Timing of subsequent new tumors in patients who present with basal cell carcinoma or cutaneous squamous cell carcinoma. JAMA Dermatol 2015; 151:382–8.
197. Nederlandse Vereniging voor Dermatologie en Venereologie (NVDV). Evidence-based Richtlijn Basaalcelcarcinoom. Utrecht, the Netherlands: NVDV, 2014.
198. Telfer NR, Colver GB, Morton CA et al. Guidelines for the management of basal cell carcinoma. Br J Dermatol 2008; 159:35–48.
199. Terrill PJ, Fairbanks S, Bailey M. Is there just one lesion? The need for whole body skin examination in patients presenting with non-melanocytic skin cancer. ANZ J Surg 2009; 79:707–12.
200. de Vries E, Micallef R, Brewster DH et al.; EPIDERM Group. Population-based estimates of the occurrence of multiple vs first primary basal cell carcinomas in 4 European regions. Arch Dermatol 2012; 148:347–54.
201. Jurciukonyte R, Vincerzevskiene I, Krilaviciute A et al. Epidemiology of basal cell carcinoma in Lithuania, 1996–2010. Br J Dermatol 2013; 169:1100–5.
202. Reinau D, Surber C, Jick SS et al. Epidemiology of basal cell carcinoma in the United Kingdom: incidence, lifestyle factors, and comorbidities. Br J Cancer 2014; 111:203–6.
203. Carsin AE, Sharp L, Comber H. Geographical, urban/rural and socioeconomic variations in nonmelanoma skin cancer incidence: a population-based study in Ireland. Br J Dermatol 2011; 164:822–9.
204. Rudolph C, Schnoor M, Eisemann N et al. Incidence trends of nonmelanoma skin cancer in Germany from 1998 to 2010. J Dtsch Dermatol Ges 2015; 13:788–97.
205. Lipozenčić J, Celić D, Strnad M et al. Skin cancers in Croatia, 2003–2005: epidemiological study. Coll Antropol 2010; 34:865–9.
206. Videnović G, Miljus D, Ilic D et al. Nonmelanoma skin cancer in the population of the city of Belgrade in the period 1999–2011. Srp Arh Celok Lek 2015; 143:290–5.
207. Bielsa I, Soria X, Esteve M et al. Population-based incidence of basal cell carcinoma in a Spanish Mediterranean area. Br J Dermatol 2009; 161:1341–6.
208. Jung GW, Metelitsa AI, Dover DC et al. Trends in incidence of nonmelanoma skin cancers in Alberta, Canada, 1988–2007. Br J Dermatol 2010; 163:146–54.
209. Demers AA, Nugent Z, Mihalcioiu C et al. Trends of nonmelanoma skin cancer from 1960 through 2000 in a Canadian population. J Am Acad Dermatol 2005; 53:320–8.
210. Karagas MR, Greenberg ER, Spencer SK et al. Increase in incidence rates of basal cell and squamous cell skin cancer in New Hampshire, USA. New Hampshire Skin Cancer Study Group. Int J Cancer 1999; 81:555–9.
211. Wu S, Han J, Li WQ et al. Basal-cell carcinoma incidence and associated risk factors in U.S. women and men. Am J Epidemiol 2013; 178:890–7.
212. Athas WF, Hunt WC, Key CR. Changes in nonmelanoma skin cancer incidence between 1977–1978 and 1998–1999 in Northcentral New Mexico. Cancer Epidemiol Biomarkers Prev 2003; 12:1105–8.
213. Harris RB, Griffith K, Moon TE. Trends in the incidence of nonmelanoma skin cancers in southeastern Arizona, 1985–1996. J Am Acad Dermatol 2001; 45:528–36.
214. Sella T, Goren I, Shalev V et al. Incidence trends of keratinocytic skin cancers and melanoma in Israel 2006–11. Br J Dermatol 2015; 172:202–7.
215. Sng J, Koh D, Siong WC et al. Skin cancer trends among Asians living in Singapore from 1968 to 2006. J Am Acad Dermatol 2009; 61:426–32.
216. Munyao TM, Othieno-Abinya NA. Cutaneous basal cell carcinoma in Kenya. East Afr Med J 1999; 76:97–100.
217. Norval M, Kellett P, Wright CY. The incidence and body site of skin cancers in the population groups of South Africa. Photodermatol Photoimmunol Photomed 2014; 30:262–5.
218. Custódio G, Locks LH, Coan MF et al. Epidemiology of basal cell carcinomas in Tubarao, Santa Catarina (SC), Brazil between 1999 and 2008. An Bras Dermatol 2010; 85:819–26.
219. Foster HM, Webb SJ. Skin cancer in the North Solomons. Aust N Z J Surg 1988; 58:397–401.
220. Richmond-Sinclair NM, Pandeya N, Ware RS et al. Incidence of basal cell carcinoma multiplicity and detailed anatomic distribution: longitudinal study of an Australian population. J Invest Dermatol 2009; 129:323–8.
221. Brougham ND, Dennett ER, Tan ST. Changing incidence of non-melanoma skin cancer in New Zealand. ANZ J Surg 2011; 81:633–6.
222. Welter D, MacArthur J, Morales J et al. The NHGRI GWAS catalog, a curated resource of SNP-trait associations. Nucleic Acids Res 2014; 42:D1001–6.